Zobrazeno 1 - 2
of 2
pro vyhledávání: '"administration & dosage [Recombinant Proteins]"'
Autor:
Biousse, Valérie, Newman, Nancy J, Esposti, Simona, La Morgia, Chiara, Priglinger, Claudia, Karanja, Rustum, Blouin, Laure, Taiel, Magali, Sahel, José-Alain, Group, LHON Study, Yu-Wai-Man, Patrick, Carelli, Valerio, Moster, Mark L, Vignal-Clermont, Catherine, Klopstock, Thomas, Sadun, Alfredo A, Sergott, Robert C, Hage, Rabih
Publikováno v:
Journal of Neuro-Ophthalmology
Journal of Neuro-Ophthalmology, Lippincott, Williams & Wilkins, 2020, 41 (3), pp.309-315. ⟨10.1097/wno.0000000000001367⟩
Journal of neuro-ophthalmology 41(3), 309-315 (2021). doi:10.1097/WNO.0000000000001367
Journal of Neuro-Ophthalmology, Lippincott, Williams & Wilkins, 2020, 41 (3), pp.309-315. ⟨10.1097/wno.0000000000001367⟩
Journal of neuro-ophthalmology 41(3), 309-315 (2021). doi:10.1097/WNO.0000000000001367
Supplemental Digital Content is Available in the Text.
Background: RESCUE and REVERSE were 2 Phase 3 clinical trials that assessed the efficacy and safety of intravitreal gene therapy with lenadogene nolparvovec (rAAV2/2-ND4) for the treatment o
Background: RESCUE and REVERSE were 2 Phase 3 clinical trials that assessed the efficacy and safety of intravitreal gene therapy with lenadogene nolparvovec (rAAV2/2-ND4) for the treatment o
Autor:
Donatella Raspadori, Francesco Lauria, Monica Bocchia, Antonio Tabilio, S Gentili, Albertina Fanelli, Alessandro Gozzetti, Francesco Forconi, Elisabetta Abruzzese, Marilina Amabile, Sergio Amadori, Francesco Iuliano
Although imatinib is the standard treatment for chronic myeloid leukaemia, not all patients reach complete cytogenetic remission (CCR) and most maintain detectable disease at the molecular level. We investigated whether a vaccine targeting the BCR-AB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd626ac704722689afd1488831bb1752
http://hdl.handle.net/11365/25596
http://hdl.handle.net/11365/25596